Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients

Publication ,  Journal Article
Zalutsky, MR; Akabani, G; Cokgor, I; Friedman, HS; Coleman, RE; Friedman, AH; McLendon, RE; Bigner, DD
Published in: EUROPEAN JOURNAL OF NUCLEAR MEDICINE
September 1, 1999

Duke Scholars

Published In

EUROPEAN JOURNAL OF NUCLEAR MEDICINE

ISSN

0340-6997

Publication Date

September 1, 1999

Volume

26

Issue

9

Start / End Page

1215 / 1215

Publisher

SPRINGER VERLAG

Related Subject Headings

  • Nuclear Medicine & Medical Imaging
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
  • 0299 Other Physical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zalutsky, M. R., Akabani, G., Cokgor, I., Friedman, H. S., Coleman, R. E., Friedman, A. H., … Bigner, D. D. (1999). Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 26(9), 1215–1215.
Zalutsky, M. R., G. Akabani, I. Cokgor, H. S. Friedman, R. E. Coleman, A. H. Friedman, R. E. McLendon, and D. D. Bigner. “Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients.” EUROPEAN JOURNAL OF NUCLEAR MEDICINE 26, no. 9 (September 1, 1999): 1215–1215.
Zalutsky MR, Akabani G, Cokgor I, Friedman HS, Coleman RE, Friedman AH, et al. Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients. EUROPEAN JOURNAL OF NUCLEAR MEDICINE. 1999 Sep 1;26(9):1215–1215.
Zalutsky, M. R., et al. “Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients.” EUROPEAN JOURNAL OF NUCLEAR MEDICINE, vol. 26, no. 9, SPRINGER VERLAG, Sept. 1999, pp. 1215–1215.
Zalutsky MR, Akabani G, Cokgor I, Friedman HS, Coleman RE, Friedman AH, McLendon RE, Bigner DD. Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients. EUROPEAN JOURNAL OF NUCLEAR MEDICINE. SPRINGER VERLAG; 1999 Sep 1;26(9):1215–1215.

Published In

EUROPEAN JOURNAL OF NUCLEAR MEDICINE

ISSN

0340-6997

Publication Date

September 1, 1999

Volume

26

Issue

9

Start / End Page

1215 / 1215

Publisher

SPRINGER VERLAG

Related Subject Headings

  • Nuclear Medicine & Medical Imaging
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
  • 0299 Other Physical Sciences